Leukemia

Journal

Publication Venue For

  • Simplified frailty assessment tools: are we really capturing frailty or something else?.  34:1967-1969. 2020
  • Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905.  34:1006-1016. 2020
  • Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.  34:358-368. 2020
  • Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years 2020
  • Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.  33:2599-2609. 2019
  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.  33:2266-2275. 2019
  • Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.  33:1620-1634. 2019
  • Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.  33:1273-1277. 2019
  • Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.  33:771-775. 2019
  • Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.  33:371-378. 2019
  • Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.  33:554-558. 2019
  • Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.  32:2706-2709. 2018
  • NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.  32:2536-2545. 2018
  • Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.  32:2352-2362. 2018
  • Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).  32:1370-1379. 2018
  • Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: An analysis of Alliance studies.  32:1338-1348. 2018
  • Treatment approaches and outcomes in plasmacytomas: Analysis using a national dataset.  32:1414-1420. 2018
  • Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.  32:575-587. 2018
  • An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.  32:510-519. 2018
  • Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). 2017
  • The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.  31:2503-2514. 2017
  • The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.  31:2267-2271. 2017
  • NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.  31:1648-1650. 2017
  • Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.  31:1450-1453. 2017
  • Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.  31:1278-1285. 2017
  • No evidence for microsatellite instability in acute myeloid leukemia.  31:1474-1476. 2017
  • The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia 2017
  • Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.  30:2364-2372. 2016
  • Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.  30:2254-2258. 2016
  • Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.  30:2214-2220. 2016
  • Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.  30:2080-2083. 2016
  • MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: A Children's Oncology Group Study.  30:1909-1912. 2016
  • Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.  30:1779-1780. 2016
  • Clinical features and gene-and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).  30:1586-1589. 2016
  • Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: A report from the Children's Oncology Group.  29:2424-2426. 2015
  • Early mortality in multiple myeloma.  29:1616-1618. 2015
  • Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.  29:567-575. 2015
  • The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.  29:233-237. 2015
  • Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements.  28:428-430. 2014
  • Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson.  28:289-292. 2014
  • An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome.  28:1015-1021. 2014
  • GAS6 expression identifies high-risk adult AML patients: Potential implications for therapy.  28:1252-1258. 2014
  • Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031.  28:1467-1471. 2014
  • Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: Opportunities for therapeutic intervention.  28:15-33. 2014
  • Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: Results from children's oncology group study AALL0031.  28:964-967. 2014
  • Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.  28:1754-1758. 2014
  • A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.  27:2023-2031. 2013
  • Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies.  27:1139-1145. 2013
  • Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: A SWOG report.  27:238-241. 2013
  • The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.  26:1713-1717. 2012
  • Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia.  25:1365-1368. 2011
  • Microarray detection of multiple recurring submicroscopic chromosomal aberrations in pediatric T-cell acute lymphoblastic leukemia.  25:1042-1046. 2011
  • Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles.  25:1555-1563. 2011
  • Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells.  25:305-312. 2011
  • Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.  25:463-472. 2011
  • Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: A report from the Bone Marrow Transplant Survivor Study.  24:2039-2047. 2010
  • Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.  24:1299-1301. 2010
  • Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.  24:779-787. 2010
  • Targeting the leukemic stem cell: The Holy Grail of leukemia therapy.  23:25-42. 2009
  • Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.  22:686-707. 2008
  • Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.  22:748-755. 2008
  • HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia.  22:1161-1169. 2008
  • Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.  22:708-722. 2008
  • Gene expression overlap affects karyotype prediction in pediatric acute lymphoblastic leukemia [17].  21:1341-1344. 2007
  • Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma [7].  21:184-187. 2007
  • A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies [4].  20:1295-1297. 2006
  • Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.  20:1254-1260. 2006
  • High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: A Children's Oncology Group (COG) initiative.  19:734-740. 2005
  • Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support.  19:98-102. 2005
  • No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities.  19:557-563. 2005
  • Nonproliferating CML CD34+ progenitor are resistant to apoptosis induced by a wide range of proapoptotic stimuli.  19:1034-1041. 2005
  • Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000.  19:2101-2116. 2005
  • JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.  18:189-218. 2004
  • RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.  18:685-692. 2004
  • Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome.  18:693-702. 2004
  • Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.  17:700-706. 2003
  • B-cell development in the presence of the MLL/AF4 oncoprotein proceeds in the absence of HOX A7 and HOX A9 expression.  17:2454-2459. 2003
  • Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.  17:2358-2382. 2003
  • AML1 gene over-expression in childhood acute lymphoblastic leukemia.  16:658-668. 2002
  • AML1 gene over-expression in childhood acute lymphoblastic leukemia..  16:658-668. 2002
  • AML1 gene over-expression in childhood acute lymphoblastic leukemia.  16:658-668. 2002
  • Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).  16:1627-1636. 2002
  • T(7;12)(q36;p13) and t(7;12)(q32;p13) - Translocations involving ETV6 in children 18 months of age or younger with myeloid disorders.  15:915-920. 2001
  • Acute lymphoblastic leukemia with an unusual t(8;14)(q11.2;q32): A Pediatric Oncology Group study.  14:238-240. 2000
  • Notch-1 and Notch-2 exhibit unique patterns of expression in human B-lineage cells.  14:2095-2102. 2000
  • Prognostic factors in children and adolescents with acute myeloid leukemia (exluding children with Down syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.  14:1201-1207. 2000
  • Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: A pediatric oncology group study.  14:1570-1576. 2000
  • Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience.  13:135-141. 1999
  • Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL, a Pediatric Oncology Group (POG) study.  13:1696-1707. 1999
  • Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.  12:1708-1717. 1998
  • Molecular analysis of the PML/RARα chimeric gene in pediatric acute promyelocytic leukemia.  10:1296-1302. 1996
  • Long-term follow-up of a randomized post-induction therapy trial in acute myeloeenous leukemia (A Southeastern Cancer Study Group Trial).  9:1456-1460. 1995
  • T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors.  9:1006-1012. 1995
  • A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.  8:1847-1853. 1994
  • Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.  8:1124-1130. 1994
  • Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: A pediatric oncology group study.  7:2064-2068. 1993
  • Childhood acute lymphoblastic leukemia with both t(1;19) and t(9;22).  6:535-540. 1992
  • The non-random dic(9;12) translocation in acute lymphoblastic leukemia is associated with B-progenitor phenotype and an excellent prognosis.  6:703-707. 1992
  • t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia.  6:251-255. 1992
  • Heterogeneity of the breakpoint localization in malignant cells with a 9p11 chromosomal abnormality.  5:468-472. 1991
  • International Standard Serial Number (issn)

  • 0887-6924
  • Electronic International Standard Serial Number (eissn)

  • 1476-5551